Screening for gastrointestinal tumors in patients
Official title: Combined Screening for Gastrointestinal Tumors
Run by Zhejiang Cancer Hospital · NCT06478030 · Data updated 2026-11-12
This study is trying to see if a series of tests and questionnaires can help identify people at high risk for gastrointestinal tumors so they can get the right screenings and care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years to 74 Years |
| Sex | All |
| Enrollment | 200000 (estimated) |
| Sponsor | Zhejiang Cancer Hospital Academic / other |
| Locations | 2 sites (Jinhua, Zhejiang and 1 other locations) |
| Status | Recruiting |
| Started | March 1, 2023 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | January 28, 2025 |
| Trial ID | NCT06478030 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are residents of Zhejiang Province who can provide informed consent and are in good physical condition.
✕Probably not a fit
Patients with severe cardiovascular, liver, or kidney diseases, or those already diagnosed with malignant tumors of the digestive tract may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study involves participants completing a comprehensive questionnaire and undergoing several tests, including a Helicobacter pylori test and a fecal immunochemical test (FIT). The collected data, which includes medical history and lifestyle factors, is entered into a cancer screening information platform for risk assessment. High-risk individuals are then recommended for further clinical screening, and various biological samples are collected for analysis. Participants are required to have at least one annual follow-up to monitor their health status.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection and better management of gastrointestinal tumors.
How similar studies have gone: Other studies have shown success in using combined screening methods for early detection of gastrointestinal tumors, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject residents from Zhejiang Province. * Subject is able to comprehend, sign, and date the written informed consent document to participate in the study. * Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study. Exclusion Criteria: * Subject has heavy cardiovascular, liver or kidney disease. * Subject is already suffering from malignant tumors of the digestive tract. * Subject has severe intellectual disabilities or language communication barriers. * Subject has had gastrointestinal endoscopy in the past year.
Where it's running
-
Yongkang City
Jinhua, Zhejiang, China Recruiting -
Fenghua District
Ningbo, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Xiangdong Cheng, MD
- Email: chengxd@zjcc.org.cn
- Phone: 13968032995
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BL-M08D in patients with digestive tract and other solid tumors
A early-stage study to see if BL-M08D1 can be safely given and help people with advanced digestive tract cancers and other solid tumors.
-
BL-ARC002 in patients with advanced solid tumors
This study tests BL-ARC002 to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors.
-
Gastrointestinal cancer screening using a multi-target detection model
A randomized trial tests whether a combined blood and stool screening approach can reduce 5-year gastrointestinal cancer deaths compared with standard routine observation.
-
SKB571 in Gastrointestinal Tumors
A Phase 2, open-label study tests SKB571 in adults with gastrointestinal tumors to see if it is safe and may help shrink tumors.
-
KQB198 plus imatinib for first-line advanced or metastatic GIST
This Phase 2 test will see if adding the experimental drug KQB198 to imatinib helps people with advanced or metastatic GIST who are starting first-line treatment.
-
BL-M24D1 treatment for advanced gastrointestinal and other solid tumors
This trial will test BL-M24D1 in adults with locally advanced or metastatic gastrointestinal and other solid tumors to see if it is safe, tolerated, and shows early signs of anti-tumor activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.